Clinical Trial

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated April 8, 2026 completion). Its status may not reflect the trial's current state.
Summary
HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-26.
Status change: Not Yet Recruiting → Recruiting 2024-07-17
Trial Details
NCT Number NCT06336707
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Solid Tumors
Enrollment 1,048 participants
Start Date 2024-04-11
Primary Completion 2026-04-08 (estimated)
Study Completion 2028-04-08 (estimated)
Updated on ClinicalTrials.gov 2024-07-18